At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 492 enrolled
Drug / intervention
LY2189265 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating LY2189265, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 492 participants across 14 sites.
Detailed Summary
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
First PostedMar 2012
Primary CompletionOct 2013
Study CompletionMay 2014
TodayJul 2026
First PostedMar 20, 2012
Enrollment StartMar 1, 2012
Primary CompletionOct 1, 2013
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.3 years ago
Interventions
LY2189265drug
Placebodrug
Liraglutidedrug